Lotus Pharmaceuticals, Inc. (LTUS)
| Market Cap | 8.20M -8.8% |
| Revenue (ttm) | 71.39M +4.3% |
| Net Income | 1.72M -91.6% |
| EPS | 0.06 -92.0% |
| Shares Out | 2.64B |
| PE Ratio | 0.05 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 881 |
| Open | 0.0031 |
| Previous Close | 0.0030 |
| Day's Range | 0.0031 - 0.0031 |
| 52-Week Range | 0.0018 - 0.0062 |
| Beta | -2.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Lotus Pharmaceuticals
Lotus Pharmaceuticals, Inc. operates as a healthcare-focused company. It focuses on participating in the healthcare and pharmaceutical industries through strategic investments, business development, partnerships, and industry integration. The company seeks opportunities across the healthcare value chain, including hospitals, pharmaceutical companies, biotechnology enterprises, medical device manufacturers, healthcare service providers, digital healthcare platforms, and other healthcare-related businesses. The company was formerly known as S.E. ... [Read more]
News
Lenz Therapeutics, Lotus enter license, commercialization agreement for LNZ100
LENZ Therapeutics (LENZ) and Lotus Pharmaceutical (LTUS) announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republi...
Amarin, Lotus Pharmaceuticals partner to commercialize Vazkepa in Southeast Asia
Amarin Corporation (AMRN) and Lotus Pharmaceuticals (LTUS) announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA across 10 countr...
Unicycive enters license, development agreement with Lotus in Republic of Korea
Unicycive Therapeutics (UNCY) announced that it has entered into an exclusive license agreement with Lotus Pharmaceutical (LTUS), a leading global pharmaceutical company, for the development and comme...